Dipole Density Mapping in Supraventricular Tachycardia (DDRAMATIC-SVT)
Dipole Density Right (and Left) Atrial Mapping and Assessment of Therapy In Complex Supraventricular Tachycardia
調査の概要
詳細な説明
The research study was conducted in multiple countries throughout the EU and Canada. The protocol and their corresponding NCT numbers are as follows:
NCT01914549 (Protocol CL-SVT-001, Site Belgium, Bruges Dr. Duytschaever = PI) NCT01875614 (Protocol CL-SVT-002, Sites in the UK, Drs. Grace, Hall, & Schilling = PIs) NCT03368781 (Protocol CL-SVT-004, Site Hamburg, Germany Prof. Willems = PI) NCT02469623 (Protocol CL-SVT-005, Site Prague, Czech Republic Prof. Neuzil = PI) NCT02469636 (Protocol CL-SVT-006, Site Santiago, Chile Dr. Bittner = PI) NCT02469649 (Protocol CL-SVT-008, Site Ontario, Canada Dr. Verma = PI)
All of the above records were combined into one as all protocols were essentially identical and one study report was written that encompasses the data/results for all protocols.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Cambridge、イギリス、CB23
- Papworth Hospital NHS Foundation Trust
-
Liverpool、イギリス、L14 3PE
- Liverpool Heart and Chest Hospital
-
Whitechapel、イギリス、E1 1BB
- Barts Health NHS Trust
-
-
-
-
Ontario
-
Newmarket、Ontario、カナダ、L3Y 2P9
- Southlake Regional Health Center
-
-
-
-
-
Prague、チェコ、150 30
- Na Homolce Hospital
-
-
-
-
-
Santiago、チリ、Región Metropolitana
- Pontificia Universidad Católica de Chile
-
-
-
-
-
Hamburg、ドイツ、D - 20246
- Elektrophysiologie Universitätsklinikum Hamburg-Eppendorf
-
-
-
-
-
Bruges、ベルギー、8000
- AZ Sint-Jan AV Cardiologie
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
- Be aged 18-75 years
- Be scheduled for ablation of an SVT due to the arrhythmia being recurrent, poorly tolerated, and /or unable to be controlled with antiarrhythmic drugs.
- Be able and willing to give informed consent
Exclusion Criteria
Have any of the following:
- implanted prosthetic, artificial, or repaired cardiac valves in the chamber being mapped
- permanent pacemaker or ICD leads in the chamber being mapped
- hypercoagulopathy or an inability to tolerate anticoagulation during the procedure
- Stents in the area of the pulmonary veins (Study CL-SVT-004 ONLY)
- MI within the prior two (2) months
- Cardiac surgery within the prior three (3) months
- Intracardiac thrombus
- Clinically significant tricuspid and/or mitral valve regurgitation or stenosis
- Cerebral ischemic event (including TIA) in the prior six (6) months
- Pregnant or nursing
- Currently enrolled in another clinical investigation
- Have a contraindication for transfemoral venous access (Study CL-SVT-004 ONLY)
- Have a contraindication for transseptal left atrial access (for patients with left atrial arrhythmias) (Study CL-SVT-004 ONLY)
- Life expectancy of less than one (1) year (Study CL-SVT-004 ONLY)
- Any health condition that, in the Investigator's opinion, would not allow the application of the investigational device (Study CL-AF-004 ONLY)
NOTE: The additional exclusion criteria for CL-SVT-004 were not expected to alter or bias the patient selection for study enrollment. While these criteria would have been assumed by other investigators as a standard of care for safe enrollment in a clinical study, the German EC approval required the additional statements.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dipole Density Mapping
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events
時間枠:7 days
|
Sites reported all adverse events throughout the study follow-up period regardless of their relationship to the device or procedure.
Each event was classified and adjudicated by the site-specific investigator.
The data were further analyzed by the Sponsor medical reviewer, providing a consistent determination of relationship to device, procedure and the subjects' underlying disease of the atrial arrhythmia condition.
|
7 days
|
|
The Number of Patients for Which Activation Maps Can be Created
時間枠:1 day
|
The primary performance endpoint was the number of subjects with successful construction of pre- and post-ablation procedure activation maps.
|
1 day
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Petr Neuzil, MD、Nemocnice na Homolce
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CL-SVT-005
- CL-SVT-002 (その他の助成金/資金番号:Acutus Medical)
- CL-SVT-001 (その他の識別子:Acutus Medical)
- CL-SVT-004 (その他の識別子:Acutus Medical)
- CL-SVT-006 (その他の識別子:Acutus Medical)
- CL-SVT-008 (その他の識別子:Acutus Medical)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。